Reviva Pharmaceuticals Holdings (RVPH)
OTHER OTC:RVPH
Want to see RVPH full AI Analyst Report?
Top Page
Reviva Pharmaceuticals Holdings
(OTC:RVPH)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.67
▼(-20.94% Downside)
Action:Upgraded
Date:06/02/26
The score is driven primarily by weak financial performance (no revenue, sustained losses, and ongoing cash burn) and negative corporate developments (Nasdaq delisting/OTCQB move). Technicals also remain bearish with price below key moving averages and negative MACD, while valuation signals are constrained by negative earnings and no dividend support.
Positive Factors
Low Leverage
Relatively low reported leverage reduces near-term solvency risk and preserves optionality to fund operations via equity or partnerships. For a pre-commercial biotech, modest debt limits interest burden and gives management structural flexibility to pursue Phase 3 work without immediate refinancing stress.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow leaves the company dependent on external financing to progress trials. Over months this drains shareholder value, increases dilution risk, and raises the probability management must secure dilutive capital before pivotal data or commercialization revenue materializes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Relatively low reported leverage reduces near-term solvency risk and preserves optionality to fund operations via equity or partnerships. For a pre-commercial biotech, modest debt limits interest burden and gives management structural flexibility to pursue Phase 3 work without immediate refinancing stress.
Read all positive factors
Reviva Pharmaceuticals Holdings (RVPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.07M
Dividend YieldN/A
Average Volume (3M)14.40M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue GrowthN/A
EPS Growth71.01%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-9.17
Shares Outstanding12,810,377
10 Day Avg. Volume22,198,486
30 Day Avg. Volume14,401,288
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.82
Enterprise Value/Market Cap-2.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.20
Forecast
1Y Price Target
$15.50Price Target Upside1723.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Reviva Pharmaceuticals Holdings Business Overview & Revenue Model
Company Description
Reviva Pharmaceuticals Holdings, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to advancing novel therapeutic solutions. The company strives to identify, develop, and commercialize treatments that address signifi...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Reviva does not have publicly disclosed recurring product revenue from commercialized drugs; its operations have historically been funded primarily through financing activities rather than sales (null...
Reviva Pharmaceuticals Holdings Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
56
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.61M | -19.83M | -29.88M | -39.21M | -24.11M | -10.10M |
| Net Income | -16.63M | -19.86M | -29.92M | -39.26M | -24.34M | -8.52M |
Balance Sheet | ||||||
| Total Assets | 23.56M | 15.92M | 15.50M | 23.70M | 18.92M | 31.40M |
| Cash, Cash Equivalents and Short-Term Investments | 22.19M | 14.44M | 13.48M | 23.37M | 18.52M | 29.69M |
| Total Debt | 231.27K | 406.88K | 458.15K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 6.12M | 7.28M | 14.69M | 17.98M | 10.53M | 2.72M |
| Stockholders Equity | 17.44M | 8.65M | 812.57K | 5.72M | 8.39M | 28.69M |
Cash Flow | ||||||
| Free Cash Flow | -20.20M | -24.59M | -33.54M | -28.32M | -18.96M | -10.67M |
| Operating Cash Flow | -20.20M | -24.59M | -33.54M | -28.32M | -18.96M | -10.67M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 37.10M | 25.56M | 23.65M | 33.17M | 7.79M | 31.60M |
Reviva Pharmaceuticals Holdings Technical Analysis
Negative
0.85
Price Trends
0.70
Negative
2.14
Negative
5.95
Negative
Market Momentum
-0.02
Negative
43.71
Neutral
28.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVPH, the sentiment is Negative. The current price of 0.85 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.70, and below the 200-day MA of 5.95, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.71 is Neutral, neither overbought nor oversold. The STOCH value of 28.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVPH.
Reviva Pharmaceuticals Holdings Risk Analysis
Reviva Pharmaceuticals Holdings disclosed 62 risk factors in its most recent earnings report. Reviva Pharmaceuticals Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Reviva Pharmaceuticals Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $31.46M | ― | -198.48% | ― | -0.46% | 96.28% | |
44 Neutral | $334.51M | -4.61 | -118.24% | ― | 138.86% | 42.14% | |
43 Neutral | $14.64M | -0.39 | -226.10% | ― | ― | 71.62% | |
42 Neutral | $8.07M | -0.25 | ― | ― | ― | 71.01% |
* Healthcare Sector Average
RVPH
Reviva Pharmaceuticals Holdings
0.58
-12.90
-95.68%
CVM
Cel-Sci
1.10
-1.19
-51.97%
PSTV
Plus Therapeutics
4.31
-0.75
-14.86%
XBIT
XBiotech
2.37
-0.23
-8.85%
PRLD
Prelude Therapeutics
4.35
3.49
405.81%
Reviva Pharmaceuticals Holdings Corporate Events
Delistings and Listing Changes
Reviva Pharmaceuticals Faces Nasdaq Delisting, Moves to OTCQB
Negative
May 13, 2026
On May 12, 2026, Reviva Pharmaceuticals Holdings received notice that a Nasdaq Hearings Panel had decided to delist its common stock from The Nasdaq Capital Market for failing to meet the $1.00 minimum bid price requirement, with trading on Nasdaq...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Reviva Updates Brilaroxazine Strategy and Funding Outlook
Neutral
Apr 15, 2026
On April 15, 2026, Reviva Pharmaceuticals issued a shareholder letter outlining business updates centered on its brilaroxazine schizophrenia program and intellectual property strategy, following a challenging year of reverse stock split and financ...
Business Operations and StrategyPrivate Placements and Financing
Reviva Pharmaceuticals Announces $10 Million Equity Offering
Positive
Mar 19, 2026
On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. entered into agreements with institutional investors for a registered public offering of common stock, pre-funded warrants and Series G and H warrants, structured at a public offering price ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.